Adial Pharmaceuticals, Inc. Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares
Adial Pharmaceuticals, Inc. (ADIL) reported Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares of 152.19 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares · last filed 2024-04-01
- Adial Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2023 was 152.19K shares, a 11.86% decline from fiscal 2022.
- Adial Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2022 was 172.68K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 6 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 9 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 12 month |
|---|---|---|---|
| 2023-12-31 | 152.19K shares 10-K · filed 2024-04-01 | ||
| 2023-09-30 | 204.06K shares 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | 208.90K shares 10-Q/A · filed 2023-10-30 | ||
| 2022-12-31 | 172.68K shares 10-K · filed 2024-04-01 | ||
| 2022-09-30 | 172.68K shares 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | 167.28K shares 10-Q/A · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |